Allergy Delabeling in Antibiotic Stewardship - Evaluations

NCT ID: NCT06967467

Last Updated: 2025-12-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-12-01

Study Completion Date

2029-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this RENEW-EVAL project is to understand the potential barriers to implementation of the RENEW intervention into the routine clinical care of patients with a hematological malignancy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The RENEW clinical intervention is designed to evaluate the impact of a comprehensive beta lactam (BL) allergy delabeling intervention on clinical outcomes among patients hospitalized with a hematologic malignancy (HM). HM patients are at a high risk of infection-related complications but are limited to antibiotic therapy based on self-reported allergies. The RENEW intervention will test the impact of a pharmacist-led BL allergy delabeling intervention on clinical outcomes and antibiotic use in hospitalized patients with HM.

The implementation of clinical interventions are often affected by non-clinical factors including workflow challenges and the beliefs of patients, their families, and clinical staff.

The RENEW-EVAL study is a concurrent mixed methods process evaluation of the RENEW intervention that aims to identify the social and behavioral factors that shape implementation of the intervention and to measure implementation outcomes including feasibility, acceptability, and fidelity.

Three types of data will be gathered by the research team as part of the RENEW-EVAL project: 1) semistructured interviews with patients and clinicians, (2) ethnographic observations of the delivery of the RENEW intervention, and 3) surveys assessing patient and clinician attitudes towards BL allergy delabeling, and implementation outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Beta Lactam Allergy in Patients With a Hematologic Malignancy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

penicillin allergy hematologic cancer allergy delabeling

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients who decline enrollment in the RENEW intervention

Patients who were approached for enrollment in the RENEW intervention but declined consent.

Semi-structured interview

Intervention Type BEHAVIORAL

Interviews designed to obtain information about patient reasons for enrolling or declining participation in the RENEW Intervention

Clinicians

Clinicians who provide clinical care to patients enrolled in the intervention.

Survey

Intervention Type BEHAVIORAL

Survey instruments will measure knowledge,attitudes, and practices surrounding allergy delabeling and antibiotic stewardship in patients with HM and perceptions of the feasibility and acceptability of the RENEW intervention

Semi-structured interview

Intervention Type BEHAVIORAL

Interviews designed to obtain information from clinicians about their perception of the implementation of the RENEW intervention

RENEW Clinical Pharmacist

The RENEW Clinical Pharmacist will screen, recruit, and consent potential participants and perform the RENEW intervention.

Ethnographic observation

Intervention Type BEHAVIORAL

Observations designed to identify communication and contextual barriers to the implementation of RENEW

Patients who enroll in the RENEW intervention

Patients who agree to actively participate in the RENEW intervention designed to identify opportunities to have the beta lactam allergy label removed from their electronic medical record.

Semi-structured interview

Intervention Type BEHAVIORAL

Interviews designed to obtain information about patient reasons for enrolling or declining participation in the RENEW Intervention

Survey

Intervention Type BEHAVIORAL

Survey which will incorporate a series of closed-ended questions eliciting attitudes about the feasibility and acceptability of the intervention, allergy delabeling and future BL antibiotic use

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Semi-structured interview

Interviews designed to obtain information about patient reasons for enrolling or declining participation in the RENEW Intervention

Intervention Type BEHAVIORAL

Survey

Survey which will incorporate a series of closed-ended questions eliciting attitudes about the feasibility and acceptability of the intervention, allergy delabeling and future BL antibiotic use

Intervention Type BEHAVIORAL

Ethnographic observation

Observations designed to identify communication and contextual barriers to the implementation of RENEW

Intervention Type BEHAVIORAL

Survey

Survey instruments will measure knowledge,attitudes, and practices surrounding allergy delabeling and antibiotic stewardship in patients with HM and perceptions of the feasibility and acceptability of the RENEW intervention

Intervention Type BEHAVIORAL

Semi-structured interview

Interviews designed to obtain information from clinicians about their perception of the implementation of the RENEW intervention

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patient participants:

* a diagnosis of a hematologic malignancy (lymphoma, leukemia, myeloma)
* a prior label applied to their medical record to indicate a beta lactam allergy
* hospitalized as an inpatient to an oncology service at the time the study is conducted

Clinician participants:

* member of the primary inpatient care team

Exclusion Criteria

Patient participants:

* meet one of the exclusionary criteria for the RENEW clinical intervention

Clinician participants:

* no exclusions
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Utah

OTHER

Sponsor Role collaborator

University of Pennsylvania

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ebbing Lautenbach

Professor of Medicine and Epidemiology

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01HS029879

Identifier Type: AHRQ

Identifier Source: secondary_id

View Link

855769

Identifier Type: -

Identifier Source: org_study_id